Confirmed: OS Better With Immunotherapy in Small Cell Lung Cancer

Share this post

A second study supports the benefit of adding an immune checkpoint inhibitor to standard chemotherapy for extensive stage, small cell lung cancer — with little additional toxicity.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply